KRAS G12S

P1, N=750, Active, not recruiting, Eli Lilly and Company | Recruiting --> Active, not recruiting

BRAF V600E was detected in 3.7%.ConclusionsWe report a rise in EOCRC in Serbia, especially in ages 45-49, and recommend policy makers to lower the screening age to 45. We present the first detailed molecular profile of Serbian EOCRC and recommend that policy makers implement routine KRAS variant testing and ensure access to KRAS G12C-targeted therapies to improve personalized care.

IsoPS-DIA is compatible with both Orbitrap and quadrupole time-of-flight mass spectrometry (Q-TOF) platforms using standard software, and we provide an open-source window-design tool to facilitate adoption. These results demonstrate the unique capability of IsoPS-DIA to bridge genotype and proteotype through precise, scalable, and reproducible quantification, offering a broadly applicable platform for precision oncology and other applications.

Six months after the surgery, metastasis was found in the liver, but at the request of the patient and their family, the decision was made not to undergo any aggressive treatment. We describe the clinical and pathological features of colorectal YST-like carcinoma that aid in its accurate diagnosis and provide treatment suggestions.

P1, N=387, Recruiting, TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | N=287 --> 387

P1/2, N=49, Recruiting, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Quantification confirmed a statistically significant increase of apoptosis in the A8 1:1 group, consistent with effective KRAS disruption in vivo. Overall, lead LNPs, particularly A8 1:1, enabled efficient and localized RNA-based gene editing that induced downstream apoptotic signaling, demonstrating a preliminary, yet promising, proof-of-concept for CRISPR/Cas9 therapy in NSCLC.

KRASmt and NRASmt are seen in 49% and 4% of mCRC, respectively. No clinically relevant differences were observed between different RASmt. KRASmt is a common subgroup for which the outcome hopefully can be improved with newly developed drugs.

The anticancer activities of SS-3091 and SS-30125 have been validated against the KRas G12D, G12C, G12V, and G12S mutants in various cancer cells. All findings underscore the potential of SS-3091 and SS-30125 as very promising active pan-KRas inhibitors.

This study introduced a preliminary integrative workflow for neoepitope identification. Findings indicate that the 21 candidate KRAS neoepitopes have the potential to be recognized by cytotoxic lymphocytes and trigger immune response. This positions them as promising elements  for anti-cancer vaccine formulations, pending successful in vitro, animal, and clinical studies.

The KRAS protein level correlated poorly with KRAS mRNA expression level and was not significantly associated with the type of mutation present. Interestingly, we found that patients with high KRAS protein level in their tumors had a better clinical outcome.

P1/2, N=72, Not yet recruiting, Sun Yat sen University Cancer Center; Sun Yat-sen University Cancer Center